Enlivex Therapeutics Ltd. (ENLV)
1.13
-0.02 (-1.74%)
At close: Jan 14, 2025, 3:59 PM
1.14
0.88%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 1.12 |
| Market Cap | 24.85M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.98 |
| PE Ratio (ttm) | -1.15 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.17 |
| Volume | 82,604 |
| Avg. Volume (20D) | 253,600 |
| Open | 1.16 |
| Previous Close | 1.15 |
| Day's Range | 1.10 - 1.19 |
| 52-Week Range | 0.81 - 4.59 |
| Beta | undefined |
About ENLV
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel....
Industry Biotechnology
Sector Healthcare
IPO Date Jul 31, 2014
Employees 71
Stock Exchange NASDAQ
Ticker Symbol ENLV
Website https://www.enlivex.com
Analyst Forecast
According to 3 analyst ratings, the average rating for ENLV stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 1050.44% from the latest price.
Buy 66.67%
Hold 0.00%
Sell 0.00%
1 month ago ·
Source
+20.37%
Elivex Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
1 month ago ·
Source
-5.24%
Enlivex Therapeutics shares are trading higher after the company announced its board approved the purchase of up to $1 million in Bitcoin.
